Updated on 30 July 2013
The FDA has yet against sounded a warning of ‘appropriate action’ against the companies that fail to implement ‘Good Manufacturing Practices.’
Singapore: With increasing number of non-compliance issues being logged against Indian drugmakers by the US FDA, this time the American regulatory body has instructed the companies to either comply or face action.
US FDA has said that they are finding contaminants like filth, pesticides and insect parts in drugs manufactured in India, however such problems have emerged from other countries as well.
The FDA has yet against sounded a warning of ‘appropriate action' against the companies that fail to implement ‘Good Manufacturing Practices.'
This month, Wockhardt and Fresenius Kabi received warning letters from the FDA on lapses in good manufacturing practices while Hospira Healthcare India and RPG Life Sciences received warnings in May.
Last week, the FDA clamped down on 15 companies globally and India's Amrutam Life Care was one of them. The company was under fire for illegal sale of drugs labeled as dietary supplement and ayurvedic products for treating diabetes.